Hemophilia A And B clinical trials

Explore recruiting hemophilia a and b clinical trials.

Recruiting hemophilia a and b studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hemophilia A And B trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

Hungary, Ireland, Czechia, Italy, Croatia, Spain +4 more

Therapeutic use (Phase IV) EU CTIS Study details

Hemophilia A And B trials by city

Hemophilia A And B in Toronto Hemophilia A And B in Vancouver Hemophilia A And B in Montreal Hemophilia A And B in Calgary Hemophilia A And B in Edmonton Hemophilia A And B in Ottawa Hemophilia A And B in Winnipeg Hemophilia A And B in Quebec City Hemophilia A And B in Hamilton Hemophilia A And B in Kitchener Hemophilia A And B in London Hemophilia A And B in Halifax Hemophilia A And B in New York Hemophilia A And B in Los Angeles Hemophilia A And B in Chicago Hemophilia A And B in Houston

Hemophilia A And B clinical trials

Recruiting hemophilia a and b studies right now

The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency

Measurement Properties in People with Hemophilia

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

Also recruiting in Europe

An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

Hemophilia A And B trials by city

Other conditions